Indivior Pharmaceuticals, Inc.
$36.28+$0.91 (+2.6%)
Last close · Data as of Nov 2, 2026
- Market cap
- $4.4B
- P/E
- 21.1x
- EV / EBITDA
- 15.1x
- Revenue
- $1.2B
- Net margin
- 16.9%
- ROCE
- 92.3%
Price chart
Technical chartScreen technicals →Hidden because the last close is more than three trading days older than the latest prices of its class.
Daily closes.
Go deeper
Technical chart: candles, 28 indicators including moving averages, RSI and MACD, drawing tools and five colour themes
Performance
Price return, before dividends, to the 2 Nov 2026 close.
- 1M
- Stale
- 3M
- Stale
- 6M
- Stale
- 1Y
- Stale
- 5Y
- Stale
- Hidden because the last close is more than three trading days older than the latest prices of its class.
52-week range
Day change +$0.91 (+2.6%) from $35 to $36 · Last close Nov 2, 2026
Best weekday to invest, historically
The same weekly amount in INDV, bought on each weekday since 2021.
News & filings
What Indivior Pharmaceuticals filed, who traded, and what's next
How to read this
"News & filings" lists what the company itself has put on record with regulators, who inside it traded, the news that names it, and the next date we know of. Filings and releases are first-hand; news is third-party and may be thin for smaller companies. A day of insider filings is one row. Nothing here is a recommendation.
AI Summary
US StockConcernShareholders' equity is negative: liabilities exceed assets.
Strengths (1)
- Return on capital employed of 92.3%.
- Prices are as of 2 Nov 2026; price-based points are paused until newer prices arrive.
- Shareholders' equity is negative, so return on equity and debt to equity are not shown.
Prices to the 2 Nov 2026 close · Financial year: fiscal 2025
Rule-based from financial data. Not advice.
About the company
Indivior Pharmaceuticals, Inc., together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and related disorders in the United States, Europe, Canada, Australia, and internationally. It develops medicines to treat substance use disorders.
Read moreShow less
Indivior Pharmaceuticals, Inc., together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and related disorders in the United States, Europe, Canada, Australia, and internationally. It develops medicines to treat substance use disorders. The company's core marketed products include SUBLOCADE buprenorphine extended-release monthly injections; and SUBOXONE Film, a buprenorphine and naloxone sublingual film. It also manufactures SUBOXONE Tablet, a buprenorphine and naloxone sublingual tablet; and SUBUTEX Tablet, a buprenorphine sublingual tablet for the treatment of opioid use disorder (OUD). In addition, the company is developing INDV-2000, a selective orexin-1 receptor antagonist that is in Phase 2 clinical trial for the treatment of moderate to severe OUD; and INDV-6001, a buprenorphine-based long-acting injectable for the treatment of OUD in collaboration with Alar Pharmaceuticals Inc. The company was formerly known as Indivior PLC. and changed its name to Indivior Pharmaceuticals, Inc. in January 2026. Indivior Pharmaceuticals, Inc. was incorporated in 2014 and is headquartered in North Chesterfield, Virginia.
- Sector
- Healthcare
- Shares outstanding
- 125.0M
Key statistics
Screen fundamentals →Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.
Valuation
- Market cap
- $4.4B
- P/E
- 21.1x
- P/B
- -44.7x
- EV / EBITDA
- 15.1x
- EV / Sales
- 3.7x
- P/S
- 3.6x
- 52-week high
- $41.83
- 52-week low
- $28.78
Profitability
- Operating margin
- 21.4%
- Net margin
- 16.9%
- EBITDA margin
- 24.5%
- ROE
- -212.1%
- ROCE
- 92.3%
- ROA
- 17.5%
- Asset turnover
- 1.03
Growth
- RevenueFY2025, the latest fiscal year in the company's growth history.
- $1.2B
- Revenue growth, 1YFY2025, the latest fiscal year in the company's growth history.
- 4.3%
- Revenue CAGR, 3YFY2025, the latest fiscal year in the company's growth history.
- 11.2%
- Net profit growth, 1YFY2025, the latest fiscal year in the company's growth history.
- 2900.0%
- Free cash flowFY2025, the latest fiscal year in the company's growth history.
- -$94.0M
Solvency
- Current ratio
- 0.71
- Debt / Equity
- -3.55
- Debt / Assets
- 0.29
- CFO / Net profit
- -0.13
- Cash / Market cap
- 4.4%
Where the revenue went
Of every $100 of FY2025 revenue, $17 was left as net income.
| From | To | Amount |
|---|---|---|
| Revenue | Cost of revenue | $246.0M |
| Revenue | Gross profit | $993.0M |
| Gross profit | Operating expenses | $728.0M |
| Gross profit | Operating income | $265.0M |
| Operating income | Pretax income | $239.0M |
| Operating income | Interest and other expense | $26.0M |
| Pretax income | Tax and other | $29.0M |
| Pretax income | Net income | $210.0M |
Revenue and net profit
Revenue grew 4.3% in FY2025; net profit is the dashed line.
| Date | Revenue | Net profit |
|---|---|---|
| FY2022 | $901.0M | -$44.0M |
| FY2023 | $1.1B | -$126.0M |
| FY2024 | $1.2B | $7.0M |
| FY2025 | $1.2B | $210.0M |
Cash flows
FY2025: -$27.0M from operations, -$94.0M free after investment (dashed).
| Date | Operating cash flow | Free cash flow |
|---|---|---|
| FY2022 | -$4.0M | -$9.0M |
| FY2023 | -$300.0M | -$353.0M |
| FY2024 | $36.0M | $5.0M |
| FY2025 | -$27.0M | -$94.0M |
Growth
Latest fiscal year 2025: each figure with its change over the year before.
- Revenue
- $1.2B+4.3%1Y
- EBITDA
- $304.0M+241.6%1Y
- Net profit
- $210.0M+2,900.0%1Y
- Cash from operations
- -$27.0M-175.0%1Y
- Free cash flow
- -$94.0M-1,980.0%1Y
- Revenue CAGR, 3Y
- 11.2%
| Year | Revenue | EBITDA | Net profit | FCF | ROE | Revenue growth 1Y | Net profit growth 1Y |
|---|---|---|---|---|---|---|---|
| FY2025 | $1.2B | $304.0M | $210.0M | -$94.0M | -212.1% | +4.3% | +2900.0% |
Monthly returns
Month-by-month returns of INDV across the years, with the seasonal pattern.
Balance sheet
What the company owns and owes at the end of FY2025.
| Line | FY2025 |
|---|---|
| Assets | $1.2B |
| Current assets | $652.0M |
| Non-current assets | $550.0M |
| Liabilities | $1.3B |
| Current liabilities | $914.0M |
| Non-current liabilities | $386.0M |
| Equity | -$99.0M |
| Paid-in capital | $112.0M |
| Retained earnings | -$243.0M |
Market cap against peers
8 peers: same sector, nearest by size.
Peers map
Healthcare companies placed by value, growth and quality; INDV highlighted.
P/E against peers
INDV trades at 21.1x earnings against a peer median of 31.9x (a 34% discount).
Not shown (no positive earnings and no EV / Sales): RadNet, Inc.
Peer comparison
Same-sector peers by market cap, with the median.
| Company | Market cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|
| Indivior Pharmaceuticals, Inc.INDVthis companyP/E ↓ discount | $4.4B | 21.1x | -44.7x | -212.1% | 15.1x |
| Ligand Pharmaceuticals IncorporatedLGND | $4.7B | 38.0x | 4.6x | 12.2% | 25.3x |
| Amneal Pharmaceuticals, Inc.AMRX | $4.3B | 59.9x | -60.9x | -101.8% | 11.1x |
| RadNet, Inc.RDNT | $4.2B | -222.6x | 3.8x | -1.7% | 16.7x |
| Veracyte, Inc.VCYT | $4.0B | 60.1x | 3.0x | 5.1% | 40.9x |
| Waystar Holding Corp.WAY | $3.9B | 34.6x | 1.0x | 2.9% | 13.6x |
| Catalyst Pharmaceuticals, Inc.CPRX | $3.8B | 17.9x | 4.0x | 22.5% | 10.6x |
| Merit Medical Systems, Inc.MMSI | $3.8B | 29.3x | 2.4x | 8.1% | 12.5x |
| ACADIA Pharmaceuticals Inc.ACAD | $3.7B | 9.5x | 3.0x | 31.9% | 30.8x |
| Peer median | — | 31.9x | 3.0x | 6.6% | 15.1x |
Year-to-date ROI
INDV since 1 January, against earlier years.
Historical volatility
INDV's day-to-day swings over 30, 60 and 180 days.
Financial statements
Income statement, balance sheet and cash flow as reported, grouped into plain-language lines.
Consolidated figures in USD, fiscal years, newest first.
Operating margin by fiscal year
| Date | Operating margin |
|---|---|
| FY2022 | 23.9% |
| FY2023 | 22.6% |
| FY2024 | 19.7% |
| FY2025 | 21.4% |
| Line | FY2025 |
|---|---|
| RevenueTotal Revenue | $1.2B |
| Cost of revenueCost Of Revenue | $246.0M |
| Gross profitGross Profit | $993.0M |
| Operating expensesOperating Expense | $728.0M |
| Research and developmentResearch And Development | $97.0M |
| Selling, general and administrativeSelling General And Administration | $634.0M |
| Other operating expensesOther Operating Expenses | -$3.0M |
| Depreciation and amortisationDepreciation And Amortization In Income Statement | — |
| Depreciation income statementDepreciation Income Statement | — |
| Total expensesTotal Expenses | $974.0M |
| Operating incomeOperating Income | $265.0M |
| Interest and other | |
| Pretax incomePretax Income | $239.0M |
| TaxTax Provision | $29.0M |
| Net incomeNet Income | $210.0M |
| Per share | |
| Supplementary |
| Line | FY2025 |
|---|---|
| AssetsTotal Assets | $1.2B |
| Current assetsCurrent Assets | $652.0M |
| Non-current assetsTotal Non Current Assets | $550.0M |
| LiabilitiesTotal Liabilities Net Minority Interest | $1.3B |
| Current liabilitiesCurrent Liabilities | $914.0M |
| Non-current liabilitiesTotal Non Current Liabilities Net Minority Interest | $386.0M |
| EquityTotal Equity Gross Minority Interest | -$99.0M |
| Supplementary |
| Line | FY2025 |
|---|---|
| Operating cash flowOperating Cash Flow | -$27.0M |
| Cash from continuing operationsCash Flow From Continuing Operating Activities | -$27.0M |
| Net income, continuing operationsNet Income From Continuing Operations | $210.0M |
| Depreciation and amortisationDepreciation And Amortization | $20.0M |
| Depreciation, amortisation and depletionDepreciation Amortization Depletion | $20.0M |
| Depreciation | $20.0M |
| Amortization cash flowAmortization Cash Flow | — |
| Amortization of intangiblesAmortization Of Intangibles | — |
| Stock-based compensationStock Based Compensation | $26.0M |
| Deferred taxDeferred Tax | -$46.0M |
| Deferred income taxDeferred Income Tax | -$46.0M |
| Operating gains and lossesOperating Gains Losses | $1.0M |
| Gain loss on investment securitiesGain Loss On Investment Securities | — |
| Gain loss on sale of PP&EGain Loss On Sale Of PPE | — |
| Unrealized gain loss on investment securitiesUnrealized Gain Loss On Investment Securities | $0.00 |
| Net foreign currency exchange gain lossNet Foreign Currency Exchange Gain Loss | $1.0M |
| Asset impairmentAsset Impairment Charge | $19.0M |
| Change in working capitalChange In Working Capital | -$257.0M |
| Other non-cash itemsOther Non Cash Items | — |
| Interest paid (operating)Interest Paid Cfo | — |
| Interest received (operating)Interest Received Cfo | — |
| Investing cash flowInvesting Cash Flow | -$66.0M |
| Cash from continuing investingCash Flow From Continuing Investing Activities | -$67.0M |
| Capital expenditureCapital Expenditure | -$67.0M |
| Purchase of PP&EPurchase Of PPE | -$66.0M |
| Sale of PP&ESale Of PPE | — |
| Net PP&E purchases and salesNet PPE Purchase And Sale | -$66.0M |
| AcquisitionsPurchase Of Business | $0.00 |
| Net acquisitions and disposalsNet Business Purchase And Sale | $0.00 |
| Purchase of investmentsPurchase Of Investment | -$20.0M |
| Sale of investmentsSale Of Investment | $20.0M |
| Net investment purchases and salesNet Investment Purchase And Sale | $0.00 |
| Purchase of intangiblesPurchase Of Intangibles | -$1.0M |
| Sale of intangiblesSale Of Intangibles | — |
| Net intangibles purchases and salesNet Intangibles Purchase And Sale | -$1.0M |
| Other investing changesNet Other Investing Changes | $1.0M |
| Financing cash flowFinancing Cash Flow | -$30.0M |
| Cash from continuing financingCash Flow From Continuing Financing Activities | -$31.0M |
| Debt issuedIssuance Of Debt | $0.00 |
| Debt repaidRepayment Of Debt | -$17.0M |
| Net debt issuedNet Issuance Payments Of Debt | -$17.0M |
| Long-term debt issuedLong Term Debt Issuance | $0.00 |
| Long-term debt repaidLong Term Debt Payments | -$17.0M |
| Net long-term debt issuedNet Long Term Debt Issuance | -$17.0M |
| Shares issuedIssuance Of Capital Stock | $2.0M |
| Common stock issuedCommon Stock Issuance | $2.0M |
| Net common stock issuedNet Common Stock Issuance | -$9.0M |
| Common stock repurchasedCommon Stock Payments | -$11.0M |
| Share buybacksRepurchase Of Capital Stock | -$11.0M |
| Stock options exercisedProceeds From Stock Option Exercised | -$5.0M |
| Other financing chargesNet Other Financing Charges | $1.0M |
| Change in cashChanges In Cash | -$123.0M |
| Effect of exchange ratesEffect Of Exchange Rate Changes | -100.0% |
| Cash at the start of the yearBeginning Cash Position | $319.0M |
| Cash at the end of the yearEnd Cash Position | $195.0M |
| Free cash flowFree Cash Flow | -$94.0M |
| Supplemental |
Learn while you research
Academy chapters picked for Indivior Pharmaceuticals, Inc. and the metrics on this page.
- 01 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
- 02 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
- 03 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read
- 04 How to Read a Cash-Flow StatementProfit can be manipulated; cash flow rarely lies.7 min read